New funding to investigate innovative treatment approach for Osteogenesis Imperfecta Dresden, 07.05.2020 The Bone Lab Dresden received another funding from the DFG to investigate a new treatment approach for Osteogenesis Imperfecta (OI), also known as “brittle bone disease”, a genetic bone disorder that is characterized by low bone mass, reduced bone strength, and fractures. Project leader, Dr. Ingo Grafe, and his research team will analyse to what extent TGF-β-inhibition can improve the treatment response to intermittent PTH treatment in OI. Dr. Grafe joined the Bone Lab and the Division of Endocrinology, Diabetes, and [...]